From Ocean to Operating Room: How Fish Skin Is Quietly Revolutionizing Wound Healing in America

A Sustainable Biologic Solution Gains Major Insurance Coverage and Proves Superior to Synthetic Alternatives in Real-World Clinical Data In the world of advanced wound care and reconstructive surgery, an unlikely…

Continue Reading From Ocean to Operating Room: How Fish Skin Is Quietly Revolutionizing Wound Healing in America

Orsini Selected as Specialty Pharmacy Partner for Newly Approved Dermatomyositis Therapy LISRAYA

As reported on PR NewsWire, Orsini has been named a specialty pharmacy partner for Priovant’s LISRAYA™ (brepocitinib), a once-daily oral treatment recently approved by the US Food and Drug Administration…

Continue Reading Orsini Selected as Specialty Pharmacy Partner for Newly Approved Dermatomyositis Therapy LISRAYA

CARDIO-TTRansform: Eplontersen Fails to Improve Cardiovascular Outcomes When Added to Standard Therapy in ATTR-CM

As reported on Healio, the phase 3 CARDIO-TTRansform study, the largest clinical trial conducted to date in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), found that adding eplontersen to contemporary…

Continue Reading CARDIO-TTRansform: Eplontersen Fails to Improve Cardiovascular Outcomes When Added to Standard Therapy in ATTR-CM

A Breakthrough 50 Years in the Making: FDA Approves First Drug to Directly Target Pancreatic Cancer’s Primary Driver

RASONQUE Represents a Watershed Moment for a Disease That Has Resisted Treatment Since RAS Was Discovered as a Cancer-Causing Gene Pancreatic cancer is among the cruelest malignancies. It develops silently,…

Continue Reading A Breakthrough 50 Years in the Making: FDA Approves First Drug to Directly Target Pancreatic Cancer’s Primary Driver

When Your Body’s Immune System Attacks Your Blood: FDA Approves First Treatment for Warm Autoimmune Hemolytic Anemia

A Rare Disease Gets Its First FDA-Approved Medicine—And It Works Differently Than Anything Available Before Imagine your immune system getting the signals completely wrong. Instead of protecting you from infection,…

Continue Reading When Your Body’s Immune System Attacks Your Blood: FDA Approves First Treatment for Warm Autoimmune Hemolytic Anemia

Beyond the Price Tag: What Generic Drug Tariffs Could Mean for Patients’ Access to Medication

Editor's Note: Patient Worthy is honored to share this article, originally written by Renzo Luzzatti, President and CEO of US-Rx Care. The White House recently announced intent to impose tariffs…

Continue Reading Beyond the Price Tag: What Generic Drug Tariffs Could Mean for Patients’ Access to Medication

FDA Announces Nationwide Recall of Certain Thyroid Medication Due to Excess Potency Risk

As reported on The Hill, Vitruvias Therapeutics has initiated a voluntary nationwide recall of a specific lot of thyroid medication after testing indicated the tablets may contain higher-than-labeled potency, according…

Continue Reading FDA Announces Nationwide Recall of Certain Thyroid Medication Due to Excess Potency Risk

Vera’s Trutakna Shows Signs of Preserving Kidney Function in IgA Nephropathy, Challenging Voyxact’s Differentiation

As reported on BioSpace, Vera Therapeutics’ newly approved IgA nephropathy (IgAN) treatment, Trutakna, is showing early evidence that it may help preserve kidney function, a benefit that had recently drawn…

Continue Reading Vera’s Trutakna Shows Signs of Preserving Kidney Function in IgA Nephropathy, Challenging Voyxact’s Differentiation

New Consensus Recommendations Aim to Strengthen Communication and Decision-Making in Neuroblastoma Care

As reported on GlobeNewswire, a newly published set of expert consensus recommendations is seeking to improve the care experience for children diagnosed with neuroblastoma and the families who support them.…

Continue Reading New Consensus Recommendations Aim to Strengthen Communication and Decision-Making in Neuroblastoma Care

Investigational Therapy Shows Promise for Guillain-Barré Syndrome in Late-Stage Testing

As reported on Newsweek, a novel experimental treatment for Guillain-Barré syndrome (GBS) may represent a major advance for patients living with the rare neurological disorder. New findings released by biotechnology…

Continue Reading Investigational Therapy Shows Promise for Guillain-Barré Syndrome in Late-Stage Testing

Mütter Museum in Philadelphia Displays Two Skeletons Who Suffered from Fibrodysplasia Ossificans Progressiva

Today the Tin Soldier Disease has a treatment. A clinical trial showed a 90% reduction in new bone development in adults with FOP. After Decades of Hope Deferred, Pasatru Offers…

Continue Reading Mütter Museum in Philadelphia Displays Two Skeletons Who Suffered from Fibrodysplasia Ossificans Progressiva

A Simple Blood Test Could Predict Which Myeloma Patients Face Hidden Neurological Danger from CAR-T Therapy

Researchers Discover That One of Medicine's Most Common Lab Tests May Warn of Rare But Serious Side Effects Weeks Before They Occur As reported on Inside Precision Medicine, CAR-T cell…

Continue Reading A Simple Blood Test Could Predict Which Myeloma Patients Face Hidden Neurological Danger from CAR-T Therapy

FDA Authorizes Lantheus’ Tau PET Imaging Agent for Alzheimer’s Disease Evaluation

As reported on Fierce BioTech, the U.S. Food and Drug Administration has granted approval to Lantheus’ positron emission tomography (PET) imaging agent Tauklarify (MK-6240), expanding diagnostic options for the assessment…

Continue Reading FDA Authorizes Lantheus’ Tau PET Imaging Agent for Alzheimer’s Disease Evaluation

When Your Cells’ Quality Control System Breaks Down: Understanding a Major Discovery in Rare Disease Research

The Basic Problem: Why One Bad Gene Can Cause Big Trouble Imagine your body as a giant factory. Like any factory, it needs quality control—machines that make sure good products…

Continue Reading When Your Cells’ Quality Control System Breaks Down: Understanding a Major Discovery in Rare Disease Research

FDA Approves Regeneron’s Pasatru for Fibrodysplasia Ossificans Progressiva, Expanding Treatment Options

As reported on BioSpace, the U.S. Food and Drug Administration has approved Regeneron’s Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder that causes bone to…

Continue Reading FDA Approves Regeneron’s Pasatru for Fibrodysplasia Ossificans Progressiva, Expanding Treatment Options